Ruxience
1 product
1 abstract
Abstract
Effect of rituximab on remissions without minimal residual disease and immunogenicity in patients with relapsed/refractory hairy cell leukemia receiving moxetumomab pasudotox.Org: Laboratory of Molecular Biology, NCI, NIH, Bethesda, MD, Laboratory of Pathology, NCI, NIH, Bethesda, MD, Office of Research Nursing, NCI, NIH, Bethesda, MD, Hematology Service, DLM, NIH, Bethesda, MD,
Product
Rituximab